FORM PTO-1449

U.S. Dept. of Commerce Patent and Trademark Office

Atty Docket No.	
P1085R4-1AC1	

Applicant

Hsei et al.	
Filing Date	Group
29 Nov 2000	1643

Serial

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date	
3AC	* 1	4,002,531	11.01.77	Royer	\			
	* 2	4,179,337	18.12.79	Davis et al.		/		
	* 3	4,732,863	22.03.88	Tomasi et al.	\			
- 1	* 4	5,147,537	15.09.92	Sada et al.	\	/		
	* 5	5,166,322	24.11.92	Shaw et al.	\	///		
1	* 6	5,169,627	08.12.92	Cunningham-Rundles	\	//		
1	* 7	5,527,528	18.06.96	Allen et al.	\ \	/		
}	* 8	5,532,150	02.07.96	Snow et al.	V			
1	* 9	5,595,732	21.01.97	Hakini et al.	\land			
}	*10	5,620,689	15.04.97	Allen et al.	/ '	\		
į	*11	5,643,575	01.07.97	Martinez et al.		\		
- 1	*12	5,661,020	26.08.97	Snow et al.				
1	*13	5,670,132	23.09.97	Griffiths et al.	/	\		
1	*14	5,677,426	14.10.97	Fong et al.	/	\		
}	*15	5,686,070	11.11.97	Doerschuk et al.				
	*16	5,695,760	09.12.97	Faanes et al.				
1	*17	5,698,196	16.12.97	Matsushima et al.				
- 1	*18	5,702,946	30.12.97	Doerschuk et al.				
_[,	*19	5,707,622	13.01.98	Fong et al.	1			
- AR	*20	5,766,897	16.06.98	Braxton, S.	/			
	FOREIGN PATENT DOCUMENTS							

FOREIGN PATENT DOCUMENTS

Examiner nitials		Document Number	Date	Country	Class	Subclass	Transla Yes	tion No
34C	*21	770,628	02.05.97	EPO				
342	*22	WO 92/04372	19.03.92	PCT			ļļ	
1	*23	WO 94/12219	09.06.94	PCT				
	*24	WO 94/21235	29.09.94	PCT		/		
	*25	WO 95/11987	04.05.95	PCT		/	l t	
	*26	WO 95/15769	15.06.95	PCT				
(*27	WO 95/23813	08.09.95	PCT	1 X	į		l
1.	*28	WO 95/23865	08.09.95	PCT	()	l 1		
	*29	WO 95/32003	30.11.95	PCT		\	l	
	*30	WO 96/02576	01.02.96	PCT Abstract Only		[\	l t	
	*31	WO 96/09325	28.03.96	PCT			[
	*32	WO 96/34015	31.10.96	PCT				l
_	*33	WO 96/40731	19.12.96	PCT				
Evaminer - A A A A A A A A A A A A A A A A A A								

Examiner

Date Considered

*Examiner: Vitial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

•				Sheet 3 of 5				
FOR	M PTO-	U.S. Dept. of Commerce	Atty Docket No.	Serial No.				
			P1085R4-1AC1	05/724258				
l lic		Patent and Trademark Office	Applicant					
LIS	ו טר טו	SCLOSURES CITED BY APPLICANT	Hsei et al.					
) (Use sev	eral sheets if necessary)	Filing Date	Group - 1643				
<u> </u>		OFFICE SIGNIFICATION AND THE STATE OF THE ST	29 Nov 2000	1644				
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.) Delgado et al., "The uses and properties of PEG-linked proteins" Critical Reviews in Therapeutic Dru								
38	*54	<u>Carrier Systems</u> 9(3-4):249-304 (1992)						
MART	*55	Deuel et al., "Amino acid sequence of human platelet factor 4"]						
JIR*	*56	Elling and Kula, "Immunoaffinity partitioning: synthesis and use coupling to bovine serum albumin and monoclonal antibodies" Biot 13(3):354-362 (Jun 1991)	echnology and Applied	d Biochemistry				
34	*57	Eno-Amooquaye et al., "Altered biodistribution of an antibody-er polyethylene glycol" <u>British Journal of Cancer</u> 73(11):1323-1327	(Jun 1996)					
xe ^t	*58	Gonzalez et al., "Humanization of Murine 6G425:An Anti-IL8 Monod IL8 to Human Neutrophils" <u>1996 Keystone Symposia on Exploring ar</u> Combining Sites (Poster) pps. 1-21 (February 1996)	nd Exploiting Antibody	y and Ig Superfamily				
)11.5.*	*59	Harding et al., "Immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes" <u>Biochimica et Biophysica Acta</u> 1327(2):181-192 (Jul 25, 1997)						
opa."	*60	Harris et al., "Synthesis and Characterization of Poly(ethylene Glycol) Derivatives" <u>J. Polym. Sci., Polym. Chem. Ed.</u> 22(2):341-352 (1984)						
JART	*61	Haselgrubler et al., "Synthesis and applications of a new poly(ethylene glycol) derivative for the crosslinking of amines with thiols" <u>Bioconjugate Chemistry</u> 6(3):242-248 (May-Jun 1995)						
34 PC	*62	Hebert et al., "Endothelial and Leukocyte Forms of IL-8: Convers Neutrophils" <u>J. Immunol.</u> 145(9):3033-3040 (Nov 1, 1990)	sion by Thrombin and I	Interactions with				
JIP.K	*63	Hebert et al., "Interleukin-8: A Review" <u>Cancer Investigation</u> 11	(6):743-750 (1993)					
	*64	Karr et al., "Use of poly(ethylene glycol)-modified antibody in 228:377-390 (1994)	cell extraction" <u>Meth</u>	nods in Enzymology				
m.	*65	Katre N., "The Conjugation of Proteins with Polyethylene Glycol of proteins to enhance their therapeutic potential." Advanced Dr	ug Delivery Reviews 1	.0(1):91-114 (1993)				
31º	*66	Kawamura et al., "Immune responses to polyethylene glycol modifi Archives of Allergy & Applied Immunology 76(4):324-330 (1985)						
ארב	*67	Kirpotin et al., "Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro" <u>Biochemistry</u> 36(1):66-75 (Jan 7, 1997)						
D1	*68	Kitamura et al., "Chemical engineering of the monoclonal antibody A7 by polyethylene glycol for targeting cancer chemotherapy" Cancer Research 51(16):4310-4315 (Aug 15, 1991)						
- Br	*69	Kitamura et al., "Polyethylene glycol modification of the monocl localization" <u>Biochemical & Biophysical Research Communications</u>	171(3):1387-1394 (Sep	28, 1990)				
not.	*70	Knauf et al., "Relationship of Effective Molecular Size to Syste Interleukin-2 Chemically Modified with Water Soluble Polymers" <u>T</u> 263(29):15064-15070 (Oct 15, 1988)	he Journal of Biologi	cal Chemistry				
Die Z	*71	Ko et al., "A sensitive enzyme-linked immunosorbent assay for hu 149:227-235 (1992)	man interleukin-8" <u>J.</u>	Immuno1. Methods				

on July 25-29, 1998) 7(Suppl. 1):73 (Jul 1998)

Lang et al., "Suppression of antibody responses in rats to murine anti-CD4 monoclonal antibodies by conjugates with monomethoxypolyethylene glycol" Immunology Letters 32(3):247-252 (May 1992)

Examiner

Date Considered

6/28/62 + 3/17/03

Koumenis et al., "Tailoring antibody fragments with PEGylation without loss in biological activity" Protein Science (Abstract 109-M, presented at the Protein Society's Twelfth Symposium in San Diego, CA

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if got in conformance and not considered. Include copy of this form with next communication to applicant.

*72

								Sheet	t <u>2</u>	of <u>5</u>
FORM	PTO-	1449		U.S. Dept. of Commerce	Atty Docket No.			Serial No.		
				Patent and Trademark Office	P108	5R4-1AC1		05/3	776 258	
				ratent and trademark office	Appli	icant				
LIST	OF DI	SCLOSURES CITED B	BY APPLICANT			et al.				
(L	Jse sev	eral sheets if necessar	y)		Filing	Date		Group		
			- <u>-</u>		25	9 Nov 2000		1643		
				FOREIGN PATENT DOCUMENTS	;					
xaminer									Transla	ition
itials		Document Number	Date	Country		Class	Subc	lass	Yes	No
DIR	*34	WO 97/10847	27.03.97	PCT						
	*35	WO 98/25971	18.06.98	PCT					ļ	l
	*36	WO 98/37200	27.08.98	PCT					ļ	
one	*37	WO 99/37779	29.07.99	PCT			`	`	1	
		·	OTHER DISCL	OSURES (Including Author, Title, Date,	Pertine	nt Pages, etc	.)			
rem				Polymer- Enzyme Adducts" Enzymes as Drugs, Holcenberg, JS; Roberts, J eds.					J eds.,	
6°	*38	New York:Wiley, C	Chapter 13, pps.	. 367-383 (1981)						
ar.				eference (Product Information), and pps. 917-918 (1994)	Product Information), 48 edition, Montvale, NJ:Medical					
	*39	ì	_							
	*40			or attachment of antibodies to st c cells" <u>Biochimica et Biophysica</u>						
3He	^40	<u> </u>	_						-	
_	*41			odification of antibody to eliming 109(1):37-42 (Apr 22, 1988)	nate in	mmune comp	lex ar	nd Fc l	oinding'	
ne.	^41									
	*42			are for the synthesis of polyethy and clearance of superoxide dist					s; effec	ts on
\$	"42	α2-macroglobulin"	Analytical Bio	ochemistry 131(1):25-33 (1983)						
4	*43	Brooks and Stocks Methods in Enzymo		acrylamide-derivatized antibody :	in dext	tran-poly(e	thyle	ene gly	/col; sy	/stems"
n'	-43									
*	*44			n with monomethoxypolyethylene gluornal of Immunology 154(7):308				ng vira	il epito	pes
75	33					· -				
ا	*45			uses of Fab' fragments from Esch H., McCafferty, J., Chiswell, D.						
و*		pps. 291-308 (199	6)							
¢*	*46			CD4 immunoadhesin with monomethoute Chemistry 5(2):133-140 (Mar-A			glyco)1) ald	lehyde v	ria
1										
ré .	*47	Chapman et al., " 17(8):780-783 (Au		ibody fragments with prolonged i	n vivo	o half-live	:s" <u>Na</u>	<u>iture</u> E	310techn	rology

Clark et al., "Long-acting growth hormones produced by conjugation with polyethylene glycol" Journal of

Davis et al., "Soluble, Nonantigenic Polyethylene Gylcol-Bound Enzymes" Biomedical Polymers: Polymeric <u>Materials and Pharmaceuticals for Biomedical Use</u>, Goldberg,E and Nakajima,A eds., New York:Academic

Cunningham-Rundles et al., "Biological activities of polyethylene-glycol immunoglobulin conjugates. Resistance to enzymatic degradation" <u>Journal of Immunological Methods</u> 152(2):177~190 (Aug 10, 1992)

Delgado et al., "Analytical partitioning of poly(ethylene glycol)-modified proteins" Journal of

Delgado et al., "Distinct Influence of PEGylation on the Tumour Localisation of Transferrin and a Tumour-Specific Fab Fragment (F9)" <u>Journal of Cellular Biochemistry</u> (Abstr. A4-101, Keystone Symposium

held at Hilton Head Island, SC, Jan 7-13 1995) Suppl. 19A:171 (1995)
Delgado et al., "Enhanced tumour specificity of an anti-carcinoembrionic antigen Fab' fragment by poly(ethylene glycol) (PEG) modification" <u>British Journal of Cancer</u> 73(2):175-182 (Jan 1996)

Date Considered
6/19/02 - 3/17/02 *Examiner: 'Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Biological Chemistry 271(36):21969-21977 (Sep. 6, 1996)

<u>Chromatography B</u> 692(2):263-272 (May 9, 1997)

448

*49

*50

*51

*52

Examiner

Press pps. 441-452 (1980)

FORM	I PTO-	1449 U.S. Dept. of Commerce	Atty Docket No.	Serial No.		
		Patent and Trademark Office	P1085R4-1AC1	05/126 5258		
1.161	OE DI	SCLOSURES CITED BY APPLICANT	Applicant			
			Hsei et al.	T 0		
((Jse sev	veral sheets if necessary)	Filing Date	Group		
			29 Nov 2000	1643 1644		
	,	OTHER DISCLOSURES (Including Author, Title, Date, I	•			
2H/E	*74	Lee and Sehon, "Suppression of reaginic antibodies with modified allergenicity of protein allergens by conjugation to polyethyler Allergy & Applied Immunology 56(2):159-170 (1978)	l allergens. I. Redu ne glycol" <u>Internati</u>	ction in onal Archives of		
74ª	*75	Mainolfi, E. et al., "Reduction of Immunogenicity of A Murine AN Chemistry" The 9th International Congress of Immunology (abstraction)				
2112	*76	Maiti et al., "Tolerogenic conjugates of xenogeneic monoclonal a glycol. I. Induction of long-lasting tolerance to xenogeneic mon Journal of Cancer Suppl. 3:17-22 (1988)	oclonal antibodies"	International		
m~~~~	*77	Maruyama et al., "Immunoliposomes bearing polyethyleneglycol-cou circulation time and high extravasation into targeted solid tumo (Aug 11, 1997)	ers in vivo" FEBS Le	tters 413(1):177-180		
oitar	*78	Maruyama et al., "Targeting efficiency of PEG-immunoliposome-con Advanced Drug Delivery Reviews 24:235-242 (1997)				
OH2	*79	Mulligan et al., "Inhibition of Lung Inflammatory Reactions in R Immunol. 150(12):5585-5595 (June 15, 1993)				
714 00	*80	Nordvall et al., "IgG and IgE antibody patterns after immunotherapy with monomethoxy polyethyleneglycol modified honey bee venom" <u>Allergy: European Journal of Allergy & Clinical Immunology</u> 41(2):89-94 (Feb 1986)				
BNI	Pedley et al., "The potential for enhanced tumour localisation by poly(ethylene glycol) modification of anti-CEA antibody" <u>British Journal of Cancer</u> 70(6):1126-1130 (Dec 1994)					
OME	*82	Sekido et al., "Prevention of lung reperfusion injury in rabbits interleukin-8" Nature 365:654-657 (October 14, 1993)	by a monoclonal and	tibody against		
511et	*83	Shahinian and Silvius, "A novel strategy affords high-yield coup liposomes" Biochimica et Biophysica Acta 1239(2):157-167 (Nov 1,	ling of antibody Fal 1995)	o' fragments to		
nit.	*84	Sharp et al., "Synthesis and application of a poly(ethylene glyc separations in aqueous polymer two-phase systems" Analytical Bio				
*3KE	*85	(Shearwater Polymers, Inc.'s January 1996 Catalog of Polyethylen	e Glycol Derivatives	s) pps. 1-50		
Jhr.	*86	St. John et al., "Immunologic Therapy for ARDS, Septic Shock, an 103:932-943 (1993)	d Multiple-Organ Fai	ilure" <u>Chest</u>		
"Jun	*87	Sticherling et al., "Immunohistochemical studies on NAP-1/IL-8 i Arch. Dermatol. Res. 284:82-85 (1992)				
Jnc"	*88	Sticherling et al., "Production and Characterization of Monoclon Neutrophil Activating Peptide NAP/IL-8" <u>J. Immunol.</u> 143(5):1628-	1634 (September 1, 1	1989)		
m	*89	Suzuki et al., "Physicochemical and biological properties of poly(ethylene glycol)-coupled immunoglobulin G. Part II. Effect of molecular weight of poly(ethylene glycol)" <u>Journal of Biomaterials Science</u> , Polymer Edition 1(2):71-84 (1989)				
*ore	*90	Suzuki et al., "Preparation and characteristics of magnetite-lab poly(ethylene glycol) derivatives" <u>Biotechnology & Applied Bioch</u>	emistry 21(Pt 3):335	5-345 (Jun 1995)		
×540	*91	Tanaka et al., "Synthesis and biological characterization of mon factor" <u>FEBS letters</u> 236(2):467-470 (Aug 1988)	ocyte-derived neutro	ophil chemotactic		
"Sir	*92	Van Damme et al., "Purification of granulocyte chemotactic peptide/interleukin-8 reveals N-terminal sequence heterogeneity similar to that of β-thromboglobulin" <u>European Journal of Biochemistry</u> 181:337-344 (1989)				
746	*93	Veronese et al., "Improvement of pharmacokinetic, immunological and stability properties of asparaginase by conjugation to linear and branched monomethoxy poly(ethylene glycol)" <u>Journal of Controlled Release</u>				

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

40:199-209 (1996)

Examiner

Date Considered

				Sheet 5 of 5					
FORM	1 PTO-1	449 U.S. Dept. of Commerce	Atty Docket No.	Serial No.					
		Patent and Trademark Office	P1085R4-1AC1	04/716158					
LIST	LIST OF DISCLOSURES CITED BY APPLICANT Hsei et al.								
(L	Jse sev	eral sheets if necessary)	Filing Date	Group					
	29 Nov 2000 1 843								
		OTHER DISCLOSURES (Including Author, Title, Date, F	• • •						
	Wie et al., "Suppression of reaginic antibodies with modified allergens. III. Preparation of tolerogen: *94 conjugates of common allergens with monomethoxypolyethylene glycols of different molecular weights by								
- Mr	<u> </u>	the mixed anhydride method" <u>International Archives of Allergy & Yoshimoto et al.</u> , "Chemical modification of tryptophanase from E							
* onl	*95	reduce its immunoreactivity towards anti-tryptophanase antibodie							
*or	*96	Yoshimura et al., "Neutrophil attractant/activation protein-1 an rabbit. cDNA cloning and their expression in spleen cells" <u>J. Im</u>	_	_					
	<u> </u>	Zapata et al., "Site-Specific Coupling of Monomethoxypoly(ethyle	ene glycol) to a Sing	le-Sulfhydryl					
* Mr	* ⁹⁷	Humanized Fab'" (poster presented at the American Society for Bi Meeting in San Francisco, CA on May 21-25, 1995) pps. 1-27		i					
St.	*98	Zapata et al., "Site-Specific Coupling of Monomethoxypoly(ethyle Humanized Fab'" <u>FASEB Journal</u> (Abstract #1288, presented at the Molecular Biology FASEB Meeting in San Francisco, CA on May 21-2	American Society for	Biochemistry and					
	· •	Molecular Biology PASES Reecing in San Francisco, CA on May 21-2	.J, 1993) 9(0).A14/9	(1993)					
	! ! !								
									
									
		· · · · · · · · · · · · · · · · · · ·	·						

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

xaminer

Date Considered